Triumvira Immunologics announced a $55 million Series A round co-led by Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures. Additional investors include Oceanpine Capital and Viva Biotech Holdings, and existing investors include Bloom Burton & Co. and the Centre for Commercialization of Cancer Immunotherapy (C3i). Triumvira will use the funding to run clinical trials of cell therapies that are directed by an alternative to CARs.

Digital health company Mobio Interactive announced that it has closed $1.8 million in a seed funding round. The round was led by Singapore-based Verge HealthTech Fund along with Atlas Asset Management, Creative Ventures and VC giant SOSV.

VoxNeuro CSO, Dr. John Connolly, is featured in a recent CTV News article about the emergence of new neurological COVID-19 symptoms associated with long-haul truckers, including confusion, trouble concentrating and memory loss that persist weeks and even months after their initial sickness. Dr. Connolly is looking at the impact the novel coronavirus can have on brain function.

ProteinQure has been named among the first cohort of Google’s Canadian Accelerator Program. Google recently announced the nine companies participating in its three-month, now-fully digital, Canadian accelerator program for early-stage tech ventures using machine learning or artificial intelligence (AI) in their business.

Emerging digital therapeutics company Mobio Interactive announces partnership with Green Shield Canada (GSC) to conduct a pilot study with the evidence-based meditation app, Am Mindfulness.

Therapure Biomanufacturing announced the signing of an agreement with VBI Vaccines Inc. for the manufacture of their coronavirus vaccine candidates.

7D Surgical has received approval from the Health Sciences Authority (HSA) in Singapore for its innovative Machine-vision Image Guidance System (MvIGS) for spinal navigation.

Variation Biotechnologies, a subsidiary of Massachusetts-based VBI Vaccines, has been awarded up to $56 million from the federal Strategic Innovation Fund to ramp up development and testing of its experimental vaccine.

Curiato presented its first clinical poster at the Society of Advanced Wound Care (SAWC) virtual symposium on July 24-26, 2020. This research presented by lead author Nicola Waters, PhD, RN, MSc, highlights Curiato’s findings from its initial trial conducted at Toronto Grace Health Centre (TGHC).

Sernova Corp., a clinical-stage regenerative medicine company developing a 'functional cure' for type 1 diabetes and other chronic diseases, announced today it has entered into an exclusive, worldwide license with the University of Miami at Coral Gables, Florida, for the commercial rights to novel conformal coating immune protection technologies.

University Professor Ted Sargent has been named the University of Toronto’s vice-president, research and innovation, and strategic initiatives for a four-year term, effective July 1.